Full-Time

Senior Director

GCP Quality Assurance

Updated on 9/3/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$266k - $344k/yr

+ Annual bonus + Long-term incentive award + Equity

Boston, MA, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday; additional on-site days may be required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Veeva
FDA Regulations
Quality Assurance (QA)
Biostatistics
Google Cloud Platform

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A bachelor’s degree in a scientific or related discipline is required.
  • At least 12 years of progressive Good Clinical Practice Quality Assurance or Clinical Quality experience within a biotechnology, pharmaceutical, or contract research organization environment is required, including significant leadership experience at the Director level or equivalent.
  • Deep knowledge of global Good Clinical Practice requirements and clinical trial oversight expectations, including ICH E6, FDA regulations, EU Clinical Trials Regulation considerations, and inspection readiness expectations.
  • Experience with electronic Trial Master File systems, clinical quality systems, and electronic GxP systems is required.
  • Demonstrated experience leading or managing Good Clinical Practice audits and regulatory inspections, including inspection preparation, conduct, response development, CAPA oversight, and follow-up.
  • Extensive experience overseeing contract research organizations, clinical vendors, investigator sites, and other Good Clinical Practice service providers in outsourced or hybrid development models.
  • Experience supporting late-stage, pivotal, or registrational clinical trials and related inspection readiness activities.
  • A strong background in risk-based quality management, ICH E6(R3) risk-proportionate approaches, quality metrics, and inspection readiness is required.
  • Experience building, scaling, or maturing Good Clinical Practice Quality Assurance capabilities in lean, virtual, or growing biotechnology organizations is required.
  • The ability to balance compliance, patient safety, data integrity, and operational execution is required.
  • The position may require at least 20% travel, including occasional overnight stays, based on business needs.
Responsibilities
  • Define, implement, and continuously mature the Good Clinical Practice Quality Assurance strategy aligned with clinical development objectives, corporate priorities, and global regulatory expectations.
  • Serve as the senior Good Clinical Practice Quality Assurance partner to Clinical Operations and cross-functional stakeholders, providing strategic guidance on Good Clinical Practice compliance, clinical quality risk management, and inspection readiness.
  • Champion a proactive culture of quality, compliance, patient safety, data integrity, and continuous improvement across clinical programs.
  • Build, lead, mentor, and develop Good Clinical Practice Quality Assurance capability and external Quality Assurance resources as the function scales.
  • Ensure Good Clinical Practice processes are phase-appropriate, risk-based, compliant, scalable, and suitable for outsourced or hybrid clinical development models.
  • Lead or provide senior Quality Assurance oversight for the development, review, approval, implementation, and lifecycle management of Good Clinical Practice-related standard operating procedures, policies, work instructions, and training materials.
  • Provide senior Quality Assurance oversight for Good Clinical Practice activities conducted internally and by contract research organizations, investigator sites, vendors, and other service providers.
  • Serve as the sponsor Quality Assurance counterpart to contract research organization Quality Assurance groups and other external partner quality functions, ensuring clear standards, escalation pathways, and issue resolution.
  • Lead Good Clinical Practice vendor qualification, risk-based audit strategy, issue escalation, performance oversight, and ongoing vendor governance using risk-based principles.
  • Review, approve, and maintain Quality Assurance oversight of Good Clinical Practice-related quality agreements, vendor oversight plans, audit plans, and CAPA commitments.
  • Provide senior Quality Assurance review of key clinical and regulatory documents to support clinical development quality and submission readiness.
  • Own the risk-based Good Clinical Practice audit program, including contract research organization audits, investigator site audits, vendor audits, Trial Master File/electronic Trial Master File audits, and system or process audits as applicable.
  • Lead Good Clinical Practice inspection readiness, inspection conduct, response development, commitment tracking, and follow-up, serving as a primary Quality Assurance contact during health authority inspections.
  • Coordinate inspection preparation activities, mock inspections, inspection logistics, response development, CAPA planning, and verification of regulatory observation closure.
  • Identify, assess, escalate, and proactively mitigate Good Clinical Practice compliance risks, including protocol deviation trends, vendor performance concerns, audit findings, and inspection readiness gaps.
Desired Qualifications
  • An advanced degree is preferred.
  • At least three years of people management is preferred.
  • Familiarity with 21 CFR Part 11, data integrity principles, and Veeva or similar platforms is preferred.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...